Total Operating Expenses: $14.7 million for Q4 2025; $54.9 million for the full year 2025. Net Loss: $14.7 million for Q4 2025; $54.7 million for the full year 2025. Achieve Life Sciences Inc ...
Hosted on MSN
Should You Hold Achieve Life Sciences (ACHV)?
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline ...
Fintel reports that on September 27, 2024, Raymond James initiated coverage of Achieve Life Sciences (NasdaqCM:ACHV) with a Strong Buy recommendation. As of September 25, 2024, the average one-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results